MYGN Myriad Genetics
- 17.830
- -0.160-0.89%
- 17.850
- +0.020+0.11%
Myriad Genetics News
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $30
TD Cowen Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $32
Scotiabank Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $34
Stephens Maintains Myriad Genetics(MYGN.US) With Hold Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Myriad Genetics(MYGN.US), With a Forecast Between $32 to $40
Scotiabank Keeps Their Buy Rating on Myriad Genetics (MYGN)
Steady Growth and Market Stability Justify Hold Rating for Myriad Genetics
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Myriad Genetics: A Buy Rating Amid Reaffirmed Strategy and Growth Potential
J.P. Morgan Maintains Myriad Genetics(MYGN.US) With Sell Rating, Maintains Target Price $20
BofA Securities Initiates Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $18
Analysts Offer Insights on Healthcare Companies: Myriad Genetics (MYGN) and Alnylam Pharma (ALNY)
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Myriad Genetics Price Target Announced at $32.00/Share by Morgan Stanley
Myriad Genetics Analyst Ratings
Morgan Stanley Initiates Myriad Genetics(MYGN.US) With Hold Rating, Announces Target Price $32
Leerink Partners Maintains Myriad Genetics(MYGN.US) With Buy Rating, Maintains Target Price $35
Maintained Buy Rating on Myriad Genetics Amid GeneSight Study Discontinuation
Jefferies Upgrades Myriad Genetics(MYGN.US) to Buy Rating, Raises Target Price to $35
Analysis
Price Target
No Data
No Data